Search

Your search keyword '"Mackean, Melanie"' showing total 168 results
Start Over Author "Mackean, Melanie"
168 results on '"Mackean, Melanie"'

2. Defining the road map to a UK national lung cancer screening programme

Author

O'Dowd, Emma L, Lee, Richard W, Akram, Ahsan R, Bartlett, Emily C, Bradley, Stephen H, Brain, Kate, Callister, Matthew E J, Chen, Yan, Devaraj, Anand, Eccles, Sinan R, Field, John K, Fox, Jesme, Grundy, Seamus, Janes, Sam M, Ledson, Martin, MacKean, Melanie, Mackie, Anne, McManus, Kieran G, Murray, Rachael L, Nair, Arjun, Quaife, Samantha L, Rintoul, Robert, Stevenson, Anne, Summers, Yvonne, Wilkinson, Louise S, Booton, Richard, Baldwin, David R, and Crosbie, Philip

Published
2023
Full Text
View/download PDF

5. 162 The LungScot study: overview of findings from a feasibility and acceptability of lung screening in Scotland

Author

Cavers, Debbie, primary, van Beek, Edwin, additional, Akram, Ahsan R, additional, Dickie, Graeme, additional, Campbell, Christine, additional, Robb, Katie A, additional, Sullivan, Frank, additional, Mackean, Melanie, additional, Neilson, Aileen, additional, Steele, Robert C, additional, Brown, Lynsey, additional, and Weller, David, additional

Published
2024
Full Text
View/download PDF

7. Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma

Author

Szlosarek, P, Creelan, B, Sarkodie, T, Nolan, L, Taylor, P, Olevsky, O, Grosso, F, Cortinovis, D, Chitnis, M, Roy, A, Gilligan, D, Kindler, H, Papadatos-Pastos, D, Ceresoli, G, Mansfield, A, Tsao, A, O’Byrne, K, Nowak, A, Steele, J, Sheaff, M, Shiu, C, Kuo, C, Johnston, A, Bomalaski, J, Zauderer, M, Fennell, D, Rybkin, I, Rolfo, C, Mackean, M, Steele, N, Franks, K, Shaw, P, Lind, M, Upadhyay, S, John, T, Karapetis, C, Srivastav, R, Mencoboni, M, Chella, A, Zilembo, N, de Marinis, F, Stella, M, Chong, I, Wang, C, Null, N, Szlosarek, Peter W., Creelan, Benjamin C., Sarkodie, Thomas, Nolan, Luke, Taylor, Paul, Olevsky, Olga, Grosso, Federica, Cortinovis, Diego, Chitnis, Meenali, Roy, Amy, Gilligan, David, Kindler, Hedy, Papadatos-Pastos, Dionysis, Ceresoli, Giovanni L., Mansfield, Aaron S., Tsao, Anne, O’Byrne, Kenneth J., Nowak, Anna K., Steele, Jeremy, Sheaff, Michael, Shiu, Chiung-Fang, Kuo, Chih-Ling, Johnston, Amanda, Bomalaski, John, Zauderer, Marjorie G., Fennell, Dean A., Rybkin, Igor I., Rolfo, Christian D., MacKean, Melanie, Steele, Nicola, Franks, Kevin, Shaw, Paul, Lind, Michael J., Upadhyay, Sunil, John, Thomas, Karapetis, Christos, Srivastav, Ratnesh, Mencoboni, Manlio, Chella, Antonio, Zilembo, Nicoletta, de Marinis, Filippo, Stella, Maria Giulia, Chong, Inn-Wen, Wang, Chin-Chou, null, null, Szlosarek, P, Creelan, B, Sarkodie, T, Nolan, L, Taylor, P, Olevsky, O, Grosso, F, Cortinovis, D, Chitnis, M, Roy, A, Gilligan, D, Kindler, H, Papadatos-Pastos, D, Ceresoli, G, Mansfield, A, Tsao, A, O’Byrne, K, Nowak, A, Steele, J, Sheaff, M, Shiu, C, Kuo, C, Johnston, A, Bomalaski, J, Zauderer, M, Fennell, D, Rybkin, I, Rolfo, C, Mackean, M, Steele, N, Franks, K, Shaw, P, Lind, M, Upadhyay, S, John, T, Karapetis, C, Srivastav, R, Mencoboni, M, Chella, A, Zilembo, N, de Marinis, F, Stella, M, Chong, I, Wang, C, Null, N, Szlosarek, Peter W., Creelan, Benjamin C., Sarkodie, Thomas, Nolan, Luke, Taylor, Paul, Olevsky, Olga, Grosso, Federica, Cortinovis, Diego, Chitnis, Meenali, Roy, Amy, Gilligan, David, Kindler, Hedy, Papadatos-Pastos, Dionysis, Ceresoli, Giovanni L., Mansfield, Aaron S., Tsao, Anne, O’Byrne, Kenneth J., Nowak, Anna K., Steele, Jeremy, Sheaff, Michael, Shiu, Chiung-Fang, Kuo, Chih-Ling, Johnston, Amanda, Bomalaski, John, Zauderer, Marjorie G., Fennell, Dean A., Rybkin, Igor I., Rolfo, Christian D., MacKean, Melanie, Steele, Nicola, Franks, Kevin, Shaw, Paul, Lind, Michael J., Upadhyay, Sunil, John, Thomas, Karapetis, Christos, Srivastav, Ratnesh, Mencoboni, Manlio, Chella, Antonio, Zilembo, Nicoletta, de Marinis, Filippo, Stella, Maria Giulia, Chong, Inn-Wen, Wang, Chin-Chou, and null, null

Abstract

IMPORTANCE Arginine deprivation using ADI-PEG20 (pegargiminase) combined with chemotherapy is untested in a randomized study among patients with cancer. ATOMIC-Meso (ADI-PEG20 Targeting of Malignancies Induces Cytotoxicity-Mesothelioma) is a pivotal trial comparing standard first-line chemotherapy plus pegargiminase or placebo in patients with nonepithelioid pleural mesothelioma. OBJECTIVE To determine the effect of pegargiminase-based chemotherapy on survival in nonepithelioid pleural mesothelioma, an arginine-auxotrophic tumor. DESIGN, SETTING, AND PARTICIPANTS Thiswas a phase 2-3, double-blind randomized clinical trial conducted at 43 centers in 5 countries that included patients with chemotherapy-naive nonepithelioid pleural mesothelioma from August 1, 2017, to August 15, 2021, with at least 12 months' follow-up. Final follow-up was on August 15, 2022. Data analysis was performed from March 2018 to June 2023. INTERVENTION Patients were randomly assigned (1:1) to receive weekly intramuscular pegargiminase (36.8mg/m2) or placebo. All patients received intravenous pemetrexed (500mg/m2) and platinum (75-mg/m2 cisplatin or carboplatin area under the curve 5) chemotherapy every 3 weeks up to 6 cycles. Pegargiminase or placebo was continued until progression, toxicity, or 24 months. MAIN OUTCOMES AND MEASURES The primary end pointwas overall survival, and secondary end points were progression-free survival and safety. Response rate by blinded independent central review was assessed in the phase 2 portion only. RESULTS Among 249 randomized patients (mean [SD] age, 69.5 [7.9] years; 43 female individuals [17.3%] and 206 male individuals [82.7%]), all were included in the analysis. The median overall survival was 9.3 months (95%CI, 7.9-11.8 months) with pegargiminase-chemotherapy as compared with 7.7 months (95%CI, 6.1-9.5 months) with placebo-chemotherapy (hazard ratio [HR] for death, 0.71; 95%CI, 0.55-0.93; P = .02). The median progression-free survival was 6.2 months (

Published
2024

10. The National Lung Matrix Trial of personalized therapy in lung cancer

Author

Middleton, Gary, Fletcher, Peter, Popat, Sanjay, Savage, Joshua, Summers, Yvonne, Greystoke, Alastair, Gilligan, David, Cave, Judith, O’Rourke, Noelle, Brewster, Alison, Toy, Elizabeth, Spicer, James, Jain, Pooja, Dangoor, Adam, Mackean, Melanie, Forster, Martin, Farley, Amanda, Wherton, Dee, Mehmi, Manita, Sharpe, Rowena, Mills, Tara C., Cerone, Maria Antonietta, Yap, Timothy A., Watkins, Thomas B. K., Lim, Emilia, Swanton, Charles, and Billingham, Lucinda

Published
2020
Full Text
View/download PDF

11. An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor

Author

Gore, Martin, Hackshaw, Allan, Brady, William E., Penson, Richard T., Zaino, Richard, McCluggage, W. Glenn, Ganesan, Raji, Wilkinson, Nafisa, Perren, Timothy, Montes, Ana, Summers, Jeffrey, Lord, Rosemary, Dark, Graham, Rustin, Gordon, Mackean, Melanie, Reed, Nicholas, Kehoe, Sean, Frumovitz, Michael, Christensen, Helen, Feeney, Amanda, Ledermann, Jonathan, and Gershenson, David M.

Published
2019
Full Text
View/download PDF

13. Early prehabilitation in suspected locally advanced and metastatic lung cancer

Author

Phillips, Iain, primary, Petrie, Rebecca, additional, Allan, Lindsey, additional, Hall, Peter, additional, Walton, Abi, additional, McMillan, Debbie, additional, Peacock, Catriona, additional, Primrose, Lorraine, additional, Vallet, Mahéva, additional, Mencnarowksi, Julie, additional, MacDonald, Neil, additional, Mackean, Melanie, additional, and Barrie, Colin, additional

Published
2023
Full Text
View/download PDF

15. Immune-Related Adverse Events, Biomarkers of Systemic Inflammation, and Survival Outcomes in Patients Receiving Pembrolizumab for Non-Small-Cell Lung Cancer.

Author

Raynes, George, Stares, Mark, Low, Samantha, Haron, Dhania, Sarwar, Hussain, Abhi, Dhruv, Barrie, Colin, Laird, Barry, Phillips, Iain, and MacKean, Melanie

Subjects
THERAPEUTIC use of monoclonal antibodies, LUNG cancer, BIOMARKERS, IMMUNE checkpoint inhibitors, CONFIDENCE intervals, INFLAMMATION, RETROSPECTIVE studies, ACQUISITION of data, REGRESSION analysis, TREATMENT effectiveness, MEDICAL records, DESCRIPTIVE statistics, RESEARCH funding
Abstract

Simple Summary: Immune checkpoint inhibitors offer the chance for the durable disease control of advanced/metastatic non-small-cell lung cancer (NSCLC). However, they come with the risk of immune-related adverse events (irAEs) which may be severe or life-threatening, or lead to long-term toxicity. We confirm that the occurrence of irAEs is associated with improved survival outcomes in patients with NSCLC treated with pembrolizumab. These survival benefits are only seen in patients with particular irAEs, or mild irAEs. Significantly, we account for the time-dependent association between time on treatment and the development of irAEs. Low levels of systemic inflammation, as defined by simple biomarkers of systemic inflammation, have previously been shown to predict the occurrence of irAEs. However, we find that their predictive power is confounded by their independent prognostic value. We suggest that these findings are taken into account by other studies investigating potential biomarkers of irAE risk. Background: Pembrolizumab monotherapy for non-small-cell lung cancer (NSCLC) expressing PD-L1 ≥ 50% doubles five-year survival rates compared to chemotherapy. However, immune-related adverse events (irAEs) can cause severe, long-term toxicity necessitating high-dose steroids and/or treatment cessation. Interestingly, patients experiencing irAEs demonstrate better survival outcomes. Biomarkers of systemic inflammation, including the Scottish Inflammatory Prognostic Score (SIPS), also predict survival in this patient group. This study examines the relationship between inflammatory status, irAEs, and survival outcomes in NSCLC. Methods: A retrospective analysis was conducted on patients with NSCLC expressing PD-L1 ≥ 50% receiving first-line pembrolizumab monotherapy at a large cancer centre in Scotland. Regression analyses were conducted to examine the relationship between SIPS, irAEs, and survival. Results: 83/262 eligible patients (32%) experienced an irAE. Dermatological, endocrine, gastrointestinal, and hepatic, but not pulmonary, irAEs were associated with prolonged PFS and OS (p <= 0.011). Mild irAEs were associated with better PFS and OS in all patients, including on time-dependent analyses (HR0.61 [95% CI 0.41–0.90], p = 0.014 and HR0.41 [95% CI 0.26–0.63], p < 0.001, respectively). SIPS predicted PFS (HR 1.60 [95% CI 1.34–1.90], p < 0.001) and OS (HR 1.69 [95% CI 1.41–2.02], p < 0.001). SIPS predicted the occurrence of any irAE in all patients (p = 0.011), but not on 24-week landmark analyses (p = 0.174). The occurrence of irAEs predicted favourable outcomes regardless of the baseline inflammatory status (p = 0.015). Conclusion: The occurrence of certain irAEs is associated with a survival benefit in patients with NSCLC expressing PD-L1 ≥ 50% receiving pembrolizumab. We find that the association between low levels of systemic inflammation and the risk of irAEs is confounded by their independent prognostic value. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. The clinical significance of loss of DNA mismatch repair in ovarian cancer patients : an immunohistochemical study

Author

Mackean, Melanie

Subjects
616.994
Abstract

Loss of mismatch repair (MMR) and, in particular, loss of MLH1 is associated with acquired cisplatin resistance of ovarian tumour cell line models. The aim of this thesis is to examine in ovarian cancer patients the clinical prognostic significance of the MMR proteins MLH1 and MSH2 when measured at disease presentation. We have developed immunohistochemistry (IHC) and a scoring system for the expression of MLH1 and MSH2 in paraffin embedded tissues. We have scored both the intensity of staining (I-score) and percentage of cells staining (%-score). We have validated this technique with good agreement in scoring over time, between blocks and between observers (inter-observer kappa scores of ³ 0.629, intra-observer kappa scores of ³ 0.646 and intra-slide kappa scores of ³ 0.583). There was a positive correlation of Ki67, (a proliferation maker), with I-MLH1, %-MLH1 and %-MSH2 scores (p=0.002; <0.001 and 0.001) but not with p53 scores. We examined prechemotherapy samples from 58 patients with a histological diagnosis of advanced ovarian carcinoma, who were then treated with primary chemotherapy regimens containing cisplatin. Advanced stage was associated with increased percentage cells positive for MLH1, MSH2 and Ki67 (p = 0.0092, 0.0049 and 0.0054 respectively). We performed a multivariate analysis allowing for known clinical prognostic factors, (i.e. type of chemotherapy given, stage, performance status and residual disease). Patients with a loss of intensity of staining for MMR proteins prechemotherapy showed a poor survival (Hazard Ratio, HR=3.64; p=0.0012) and poor progression free survival (HR=2.37; p=0.016). Similarly patients showing a reduced intensity of MLH1 staining showed a poor overall survival (HR=2.17; p=0.031). There was no correlation of MMR proteins and tumour response to treatment. Although further prospective validation studies will be necessary, our observations support the proposal that low MLH1 and/or MSH2 expression is associated with resistance in vivo of ovarian tumours to cisplatin and hence poor survival of patients after cisplatin-based chemotherapy.

Published
2002

18. Table S5 from Structural Variants at the BRCA1/2 Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma

Author

Ewing, Ailith, primary, Meynert, Alison, primary, Churchman, Michael, primary, Grimes, Graeme R., primary, Hollis, Robert L., primary, Herrington, C. Simon, primary, Rye, Tzyvia, primary, Bartos, Clare, primary, Croy, Ian, primary, Ferguson, Michelle, primary, Lennie, Mairi, primary, McGoldrick, Trevor, primary, McPhail, Neil, primary, Siddiqui, Nadeem, primary, Dowson, Suzanne, primary, Glasspool, Rosalind, primary, Mackean, Melanie, primary, Nussey, Fiona, primary, McDade, Brian, primary, Ennis, Darren, primary, McMahon, Lynn, primary, Matakidou, Athena, primary, Dougherty, Brian, primary, March, Ruth, primary, Barrett, J. Carl, primary, McNeish, Iain A., primary, Biankin, Andrew V., primary, Roxburgh, Patricia, primary, Gourley, Charlie, primary, and Semple, Colin A., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Information from Structural Variants at the BRCA1/2 Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma

Author

Ewing, Ailith, primary, Meynert, Alison, primary, Churchman, Michael, primary, Grimes, Graeme R., primary, Hollis, Robert L., primary, Herrington, C. Simon, primary, Rye, Tzyvia, primary, Bartos, Clare, primary, Croy, Ian, primary, Ferguson, Michelle, primary, Lennie, Mairi, primary, McGoldrick, Trevor, primary, McPhail, Neil, primary, Siddiqui, Nadeem, primary, Dowson, Suzanne, primary, Glasspool, Rosalind, primary, Mackean, Melanie, primary, Nussey, Fiona, primary, McDade, Brian, primary, Ennis, Darren, primary, McMahon, Lynn, primary, Matakidou, Athena, primary, Dougherty, Brian, primary, March, Ruth, primary, Barrett, J. Carl, primary, McNeish, Iain A., primary, Biankin, Andrew V., primary, Roxburgh, Patricia, primary, Gourley, Charlie, primary, and Semple, Colin A., primary

Published
2023
Full Text
View/download PDF

20. Real-World Impact of SABR on Stage I Non-Small-Cell Lung Cancer Outcomes at a Scottish Cancer Centre

Author

Stares, Mark, Lewis, Georgina, Vallet, Maheva, Killean, Angus, Tramonti, Giovanni, Patrizio, Ailsa, Mackean, Melanie, Harrow, Stephen, Barrie, Colin, MacLennan, Kirsty, Campbell, Sorcha, Evans, Tamasin, Tufail, Aisha, Programme, Edinburgh Cancer Informatics Programme Edinburgh Cancer Informatics, Hall, Peter, and Phillips, Iain

Subjects
Cancer Research, stereotactic ablative radiotherapy, Oncology, real-world clinical data, non small-cell lung cancer, stage I
Abstract

Introduction: Stereotactic ablative body radiotherapy (SABR) offers patients with stage I non-small-cell lung cancer (NSCLC) a safe, effective radical therapy option. The impact of introducing SABR at a Scottish regional cancer centre was studied. Methods: The Edinburgh Cancer Centre Lung Cancer Database was assessed. Treatment patterns and outcomes were compared across treatment groups (no radical therapy (NRT), conventional radical radiotherapy (CRRT), SABR and surgery) and across three time periods reflecting the availability of SABR (A, January 2012/2013 (pre-SABR); B, 2014/2016 (introduction of SABR); C, 2017/2019, (SABR established)). Results: 1143 patients with stage I NSCLC were identified. Treatment was NRT in 361 (32%), CRRT in 182 (16%), SABR in 132 (12%) and surgery in 468 (41%) patients. Age, performance status, and comorbidities correlated with treatment choice. The median survival increased from 32.5 months in time period A to 38.8 months in period B to 48.8 months in time period C. The greatest improvement in survival was seen in patients treated with surgery between time periods A and C (HR 0.69 (95% CI 0.56–0.86), p < 0.001). The proportion of patients receiving a radical therapy rose between time periods A and C in younger (age ≤ 65, 65–74 and 75–84 years), fitter (PS 0 and 1), and less comorbid patients (CCI 0 and 1–2), but fell in other patient groups. Conclusions: The introduction and establishment of SABR for stage I NSCLC has improved survival outcomes in Southeast Scotland. Increasing SABR utilisation appears to have enhanced the selection of surgical patients and increased the proportion of patients receiving a radical therapy.

Published
2023
Full Text
View/download PDF

21. Real-World Impact of SABR on Stage I Non-Small Cell Lung 2 Cancer Outcomes at a Scottish Cancer Centre

Author

Stares, Mark, Lewis, Georgina, Vallet, Maheva, Killean, Angus, Tramonti, Giovanni, Patrizio, Ailsa, Mackean, Melanie J, Harrow, Stephen, Barrie, Colin, Maclennan, Kirsty, Campbell, Sorcha, Evans, Tamasin, Tufail, Aisha, Hall, Peter S, and Phillips, Iain

Subjects
stereotactic ablative radiotherapy, real-world clinical data, Non small cell lung cancer, stage 1
Abstract

Introduction: Stereotactic ablative body radiotherapy (SABR) offers patients with stage I 28 non small-cell lung cancer (NSCLC) a safe, effective radical therapy option. The impact of introduc-29 ing SABR at a Scottish regional cancer centre was studied. Methods: The Edinburgh Cancer Centre 30 Lung Cancer Database was assessed. Treatment patterns and outcomes were compared across treat-31 ment groups (no radical therapy (NRT), conventional radical radiotherapy (CRRT), SABR and sur-32 gery) and across 3 time periods reflecting the availability of SABR (A, January 2012/2013 (pre-33 SABR); B, 2014/ 2016 (introduction of SABR); C, 2017/2019, (SABR established). Results: 1143 pa-34 tients with stage I NSCLC were identified. Treatment was NRT in 361 (32%), CRRT in 182 (16%), 35 SABR in 132 (12%) and surgery in 468 (41%) of patients. Age, performance status and comorbidities 36 correlated with treatment choice. Median survival increased from 32.5 months in time period A to 37 38.8 months in period B to 48.8 months in time period C. The greatest improvement in survival was 38 seen in patients treated with surgery between time periods A and C (HR 0.69 (95%CI 0.56-0.86), 39 p

Published
2023

22. Publisher Correction: The National Lung Matrix Trial of personalized therapy in lung cancer

Author

Middleton, Gary, Fletcher, Peter, Popat, Sanjay, Savage, Joshua, Summers, Yvonne, Greystoke, Alastair, Gilligan, David, Cave, Judith, O’Rourke, Noelle, Brewster, Alison, Toy, Elizabeth, Spicer, James, Jain, Pooja, Dangoor, Adam, Mackean, Melanie, Forster, Martin, Farley, Amanda, Wherton, Dee, Mehmi, Manita, Sharpe, Rowena, Mills, Tara C., Cerone, Maria Antonietta, Yap, Timothy A., Watkins, Thomas B. K., Lim, Emilia, Swanton, Charles, and Billingham, Lucinda

Published
2020
Full Text
View/download PDF

23. Optimizing the implementation of lung cancer screening in Scotland: Focus group participant perspectives in the LUNGSCOT study

Author

Cavers, Debbie, primary, Nelson, Mia, additional, Rostron, Jasmin, additional, Robb, Kathryn A., additional, Brown, Lynsey R., additional, Campbell, Christine, additional, Akram, Ahsan R., additional, Dickie, Graeme, additional, Mackean, Melanie, additional, van Beek, Edwin J. R., additional, Sullivan, Frank, additional, Steele, Robert J., additional, Neilson, Aileen R., additional, and Weller, David, additional

Published
2022
Full Text
View/download PDF

24. Treatment outcomes for stage I lung cancer in south-east Scotland

Author

Lewis, Georgina, primary, Phillips, Iain, additional, Evans, Tamasin, additional, Campbell, Sorcha, additional, Maclennan, Kirsty, additional, Tufail, Aisha, additional, Fullerton, Ruth, additional, Mactier, Karen, additional, Finn, David, additional, Patrizio, Ailsa, additional, and MacKean, Melanie, additional

Published
2022
Full Text
View/download PDF

25. Real-world outcomes for patients with inoperable stage III non-small cell lung cancer: a prognostic role for albumin?

Author

Leach, James, primary, Stares, Mark, additional, Langley, Benjamin, additional, Fenner, Florence, additional, Killean, Angus, additional, Barrie, Colin, additional, Maclennan, Kirsty, additional, Campbell, Sorcha, additional, Evans, Tamasin, additional, Tufail, Aisha, additional, Harrow, Stephen, additional, McMenemy, Maria, additional, Mackean, Melanie, additional, and Phillips, Iain, additional

Published
2022
Full Text
View/download PDF

26. The Scottish Inflammatory Prognostic Score (SIPS) identifies poor responders to first-line chemoimmunotherapy in non-small cell lung cancer

Author

Raynes, George, primary, Price, Gareth, additional, Yan, Xiangfei, additional, Barrie, Colin, additional, Maclennan, Kirsty, additional, Campbell, Sorcha, additional, Evans, Tamasin, additional, Tufail, Aisha, additional, Harrow, Stephen, additional, MacKean, Melanie, additional, Philips, Iain, additional, and Stares, Mark, additional

Published
2022
Full Text
View/download PDF

27. Adjuvant durvalumab post-chemoradiotherapy in stage III non-small cell lung cancer: experience from the Edinburgh Cancer Centre

Author

Yan, Xiangfei, primary, Price, Gareth, additional, Raynes, George, additional, Stares, Mark, additional, Evans, Tamasin, additional, Campbell, Sorcha, additional, Tufail, Aisha, additional, MacLennan, Kirsty, additional, Barrie, Colin, additional, MacKean, Melanie, additional, Harrow, Stephen, additional, and Phillips, Iain, additional

Published
2022
Full Text
View/download PDF

28. Biomarkers of systemic inflammation predict survival in stage III non-small cell lung cancer treated with chemoradiotherapy

Author

Langley, Benjamin, primary, Leach, James, additional, Fenner, Florence, additional, Killean, Angus, additional, Barrie, Colin, additional, Maclennan, Kirsty, additional, Campbell, Sorcha, additional, Evans, Tamasin, additional, Tufail, Aisha, additional, Harrow, Stephen, additional, McMenemy, Maria, additional, MacKean, Melanie, additional, Phillips, Iain, additional, and Stares, Mark, additional

Published
2022
Full Text
View/download PDF

29. Hypoalbuminaemia as a Prognostic Biomarker of First-Line Treatment Resistance in Metastatic Non-small Cell Lung Cancer

Author

Stares, Mark, primary, Swan, Amanda, additional, Cumming, Kirsten, additional, Ding, Tze-En, additional, Leach, James, additional, Stratton, Cory, additional, Thomson, Findlay, additional, Barrie, Colin, additional, MacLennan, Kirsty, additional, Campbell, Sorcha, additional, Evans, Tamasin, additional, Tufail, Aisha, additional, Harrow, Stephen, additional, MacKean, Melanie, additional, and Phillips, Iain, additional

Published
2021
Full Text
View/download PDF

32. Scottish Immunotherapy Prognostic Score: biomarker of systemic inflammation predicts response to first-line pembrolizumab for metastatic non-small cell lung cancer

Author

Ding, Tze-en Grace, primary, Thomson, Findlay, additional, Stratton, Cory, additional, Cumming, Kirsten, additional, Barrie, Colin, additional, Maclennan, Kirsty, additional, Evans, Tamasin, additional, Campbell, Sorcha, additional, Tufail, Aisha, additional, Mackean, Melanie, additional, Phillips, Iain, additional, and Stares, Mark, additional

Published
2021
Full Text
View/download PDF

39. Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome

Author

Hollis, Robert L, primary, Thomson, John P, additional, Stanley, Barbara, additional, Churchman, Michael, additional, Meynert, Alison M, additional, Rye, Tzyvia, additional, Bartos, Clare, additional, Iida, Yasushi, additional, Croy, Ian, additional, Mackean, Melanie, additional, Nussey, Fiona, additional, Okamoto, Aikou, additional, Semple, Colin A, additional, Gourley, Charlie, additional, and Herrington, C. Simon, additional

Published
2020
Full Text
View/download PDF

46. Molecular stratification of endometrioid ovarian carcinomas.

Author

Stanley, Barbara, primary, Thomson, John P, additional, Hollis, Robert L, additional, Meynert, Alison, additional, Rye, Tzyvia, additional, Iida, Yasushi, additional, Nussey, Fiona, additional, Mackean, Melanie J, additional, Churchman, Michael, additional, Semple, Colin, additional, Okamoto, Aikou, additional, Gourley, Charlie, additional, and Herrington, C Simon, additional

Published
2019
Full Text
View/download PDF

48. Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations

Author

Hollis, Robert L., primary, Meynert, Alison M., additional, Churchman, Michael, additional, Rye, Tzyvia, additional, Mackean, Melanie, additional, Nussey, Fiona, additional, Arends, Mark J., additional, Sims, Andrew H., additional, Semple, Colin A., additional, Herrington, C. Simon, additional, and Gourley, Charlie, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results